Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Variability in newborn screening across Canada: spinal muscular atrophy and beyond

Author:Groulx-Boivin, Emilie   Osman, Homira   Chakraborty, Pranesh   Lintern, Stacey   Oskoui, Maryam   Selby, Kathy   Van Caeseele, Paul   Wyatt, Alexandra   McMillan, Hugh   

Session Name:P4: Health Care Disparities: Dementia, Movement, Neuromuscular, MS  

Topic:Health Care Disparities  

Program Number:P4.002  

Author Institution:Mcgill University, Montreal, QC, Canada  Muscular Dystrophy Canada and Neuromuscular Disease Network of Canada, Toronto, ON, Canada  Children's Hospital of Eastern Ontario, Ottawa, ON, Canada  Muscular Dystrophy Canada, Toronto, ON, Canada  Montreal Children's Hospital, Montreal, QC, Canada  British Columbia's Children's Hospital, Vancouver, BC, Canada  Cadham Provincial Laboratory, Winnipeg, MB, Canada  

Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial

Author:Traboulsee, Anthony   Fox, Robert   Arnold, Douglas   Syed, Sana   Orogun, Larry   Dukovic, Deborah   Turner, Timothy   Reich, Daniel   Oh, Jiwon   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.006  

Author Institution:University of British Columbia, Vancouver, BC, Canada  Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  National Institute of Neurological Disorders and Stroke, Bethesda, MD  St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada  

MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results

Author:Reich, Daniel   Traboulsee, Anthony   Syed, Sana   Xu, Zhixing   Turner, Timothy   Arnold, Douglas   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.012  

Author Institution:National Institute of Neurological Disorders and Stroke, Bethesda, MD  University of British Columbia, Vancouver, BC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  

MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study

Author:Fox, Robert   Oh, Jiwon   Arnold, Douglas   Syed, Sana   Xu, Zhixing   Turner, Timothy   Traboulsee, Anthony   Reich, Daniel   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.017  

Author Institution:Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH  St Michael's Hospital, University of Toronto, Toronto, ON, Canada  NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada  Sanofi, Cambridge, MA  Sanofi, Bridgewater, NJ  University of British Columbia, Vancouver, BC, Canada  National Institute of Neurological Disorders and Stroke, Bethesda, MD  

Myelin Water Fraction of Slowly Evolving Lesions is Associated With Disability in Multiple Sclerosis

Author:Zhuang, Rebecca   Vavasour, Irene   Elliott, Colm   Arnold, Douglas   Clayton, David   Magon, Stefano   Bonati, Ulrike   Bernasconi, Corrado   Gaetano, Laura   Traboulsee, Anthony   Kolind, Shannon   

Session Name:P10: MS Neuroimaging 1  

Topic:MS and Inflammatory Disease  

Program Number:P10.017  

Author Institution:University of British Columbia, Vancouver, BC, Canada  NeuroRx Research, Montreal, QC, Canada  Montreal Neurological Institute, McGill Univ, Montreal, QC, Canada  Genentech Inc, South San Francisco, CA  F.Hoffmann-La Roche Ltd, Basel, Switzerland